Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma

Melanoma Research

Volumn 20, Issue 4, 2010, Pages 293-302

  Šamija, Ivan ^a   Lukač, Josip ^a   Marić Brozić, Jasmina ^a   Buljan, Marija ^a   Alajbeg, Iva ^b   Kovačević, Dujo ^a   Šitum, Mirna ^a   Kusić, Zvonko ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

biological tumor markers; circulating neoplastic cells; melanoma; melanoma prognosis; melanoma survival; microphthalmia associated transcription factor; monophenol monooxygenase; neoplasm metastasis; reverse transcriptase PCR

Indexed keywords

MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOPHENOL MONOOXYGENASE; RNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; MONONUCLEAR CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; BLOOD; ENZYMOLOGY; GENETICS; MIDDLE AGED; PATHOLOGY; SECONDARY; TUMOR EMBOLISM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77954658217     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32833906b6     Document Type: Article

References (61)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.
2. Berwick M, Weinstock MA. Epidemiology, current trends. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, editors. Cutaneous melanoma. 4th ed. St Louis (MO): Quality Medical Publishing; 2003. pp. 439-448.
3. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
4. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338:1227-1229.
5. Ponnazhagen S, Hou L, Kwon BS. Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region. J Invest Dermatol 1994; 102:744-748.
6. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol 2001; 137:325-330.
7. Jin HY, Yamashita T, Minamitsuji Y, Omori F, Jimbow K. Detection of tyrosinase and tyrosinase-related protein 1 sequences from peripheral blood of melanoma patients using reverse transcription-polymerase chain reaction. J Dermatol Sci 2003; 33:169-176.
8. Samija M, Juretić A, Solarić M, Samija I, Bingulac-Popović J, Grahovac B, et al. RT-PCR detection of tyrosinase, gp100, MART1/Melan-A, and TRP-2 gene transcripts in peripheral blood of melanoma patients. Croat Med J 2001; 42:478-483.
9. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005; 23:8057-8064.
10. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999; 141:30-36.
11. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Franzke A, Sel S, et al. Tumour microdissemination and survival in metastatic melanoma. Anticancer Res 2000; 20:3619-3624.
12. Mellado B, Del Carmen Vela M, Colomer D, Gutierrez L, Castel T, Quinto L, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol 2002; 20:4032-4039.
13. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res 1999; 5:1843-1848.
14. Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, et al. Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon. Br J Cancer 2002; 87:181-186.
15. Curry BJ, Myers K, Hersey P. Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res 2001; 158:211-230.
16. Proebstle TM, Jiang W, Hogel J, Keilholz U,Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Br J Cancer 2000; 82:118-123.
17. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol 1996; 14:2091-2097.
18. Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G, et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995; 131:443-447.
19. Kunter U, Buer J, Probst M, Duensing S, Dallmann I, Grosse J, et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst 1996; 88:590-594.
20. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res 2002; 12:325-334.
21. Osella-Abate S, Savoia P, Quaglino P, Fierro MT, Eporati C, Ortoncelli M, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer 2003; 89:1457-1462.
22. Brownbridge GG, Gold J, Edward M, MacKie RM. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptasecoupled- polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol 2001; 144:279-287.
23. Quereux G, Denis M, Khammari A, Lustenberger P, Dreno B. Prognostic value of tyrosinase reverse-transcriptase polymerase chain reaction in metastatic melanoma. Dermatology 2001; 203:221-225.
24. Kulik J, Nowecki ZI, Rutkowski P, Ruka W, Rochowska M, Skurzak H, et al. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Res 2001; 11:65-73.
25. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995; 13:2109-2116.
26. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16:1760-1769.
27. Bitisik O, Camlica H, Duranyildiz D, Tas F, Kurul S, Dalay N. Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy. J Biochem Mol Biol 2003; 36:173-178.
28. Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res 2003; 9:1497-1502.
29. Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res 2000; 60:2253-2257.
30. Palmieri G, Ascierto PA, Perrone F, Satriano SM, Ottaiano A, Daponte A, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003; 21:767-773.
31. Palmieri G, Satriano SM, Budroni M, Cossu A, Tanda F, Canzanella S, et al. Serial detection of circulating tumour cells by reverse transcriptasepolymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006; 6:266.
32. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardo T, Fierro MT, et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res 2007; 17:75-82.
33. Waldmann V, Wacker J, Deichmann M, Jackel A, Bock M, Naher H. Prognosis of metastatic melanoma: no correlation of tyrosinase mRNA in bone marrow and survival time. Recent Results Cancer Res 2001; 158:118-125.
34. Ranieri JM, Wagner JD, Wiebke EA, Azuaje R, Smith ML, Wenck S, et al. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma. Plast Reconstr Surg 2005; 115:1058-1063.
35. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24:2849-2857.
36. Rutkowski P, Nowecki ZI, Kulik J, RukaW, Siedlecki JA. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Res 2008; 18:246-252.
37. Samija I, Lukac J, Maric-Brozic J, Kusic Z. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croat Med J 2004; 45:142-148.
38. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006; 12:1137-1143.
39. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006; 12:406-414.
40. Vachtenheim J, Novotna H. Expression of genes for microphthalmia isoforms, pax3 and msg1, in human melanomas. Cell Mol Biol 1999; 45:1075-1082.
41. Selzer E,Wacheck V, Lucas T, Heere-Ress E,Wu M,Weilbaecher KN, et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 2002; 62:2098-2103.
42. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436:117-122.
43. Goding C, Meyskens FL. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clin Cancer Res 2006; 12:1069-1073.
44. King R, Weilbaecher KN, McGill G, Cooley E, Mihm M, Fisher DE. Microphthalmia transcription factor a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999; 155:731-738.
45. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Microphthalmia transcription factor: a new prognostic marker in intermediatethickness cutaneous malignant melanoma. Cancer Res 2000; 60:5012-5016.
46. Granter SR,Weilbaecher KN, Quigley C, Fisher DE. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. Appl Immunohistochem 2002; 10:47-51.
47. Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S, et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 2007; 14:357-365.
48. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48:206-208.
49. Boyum A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand J Clin Lab Invest 1968; 21 (Suppl 97):51-55.
50. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
51. Tassabehji M, Newton VE, Read AP. Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene. Nature Genet 1994; 8:251-255.
52. Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer 1988; 41:248-255.
53. Lin L, Gerth AJ, Peng SL. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J Exp Med 2004; 200:115-122.
54. Medic S, Pearce RL, Heenan PJ, Ziman M. Molecular markers of circulating melanoma cells. Pigment Cell Res 2007; 20:80-91.
55. Samija I, Lukac J, Kusic Z, Situm M, Samija M. Detection of disseminated melanoma cells by reverse-transcription-polymerase chain reaction. Coll Antropol 2007; 31:1187-1194.
56. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92:8125-8129.
57. Murakami M, Iwata Y, Funaba M. Expression and transcriptional activity of alternative splice variants of MITF exon 6. Mol Cell Biochem 2007; 303:251-257.
58. Palmieri G, Casula M, Sini MC, Ascierto PA, Cossu A. Issues affecting molecular staging in the management of patients with melanoma. J Cell Mol Med 2007; 11:1052-1068.
59. Carreira S, Goodall J, Denat L, Rodriguez M, Nuciforo P, Hoek KS, et al. MITF regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006; 20:3426-3439.
60. Ugurel S, Houben R, Schrama D, Voigt H, Zapatka M, Schadendorf D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res 2007; 13:6344-6350.
61. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res 2004; 14:S17-S19.